Eslicarbazepine acetate

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Eslicarbazepine acetate

Examples of brand names: Zebinix [EU]

ATC code: N03AF04

Main use (for orientation): Focal seizures with/without secondary generalisation; monotherapy or adjunctive treatment depending on patient group

Documented research summary

Existing CBD findings were not linked under the metabolite name. The UAB analyses provide different signals and overlap; do not count as independent confirmation.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Direct pair finding

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Pair-specific evidence, distinguished in the individual findings

Mechanism / drug context: Eslicarbazepine is measured as the active metabolite of the prodrug eslicarbazepine acetate.

Type of supporting material: See the separate original findings

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Eslicarbazepine acetate tablets, Camber US; focal seizures from age 4. Sodium-channel modulation mainly by the active metabolite; the acetate is not identical to measured eslicarbazepine. Hyponatraemia/CNS effects are drug risks.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0043]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE) TABLET [CAMBER PHARMACEUTICALS, INC.] [C_LABEL_D0043]

Source role [CL20]: Existing pair finding

Statement supported: Eslicarbazepine as active metabolite, B0060; no new double counting.

Source: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

Source role [CL21]: Existing pair finding

Statement supported: Earlier overlapping UAB analysis, B0078; not independent confirmation.

Source: Interactions between cannabidiol and commonly used antiepileptic drugs [CL21]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: Complete saved individual review, label assessment, literature screening, conclusion and uncertainties read. Original information selectively rechecked by section; no complete revalidation of all prescribing information or full texts claimed. Existing findings linked, not a new patient dataset; current full-text access partly restricted by browser checks.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0060

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.7122.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: The active metabolite eslicarbazepine during eslicarbazepine acetate treatment was investigated, not a separate assessment of prodrug plasma concentration. n=12.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context/limitations CL20; absence of significance does not establish equivalence. B0060 and B0078 originate from the same UAB study family (earlier and expanded analyses); do not count as two independent replications.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

CBD – clinical signals

Finding ID: B0078

Type of result: Positive finding / indication

Observation: Concentration increase associated with CBD dose.

Mechanism: Mechanism uncertain

Study type: Open-label observational study

Context studied: The active metabolite eslicarbazepine during eslicarbazepine acetate treatment was investigated, not a separate assessment of prodrug plasma concentration. 81 in total; adults only.

Clinical interpretation: Unclear

Limitations and uncertainties: Consider CL20 as a later analysis, not independent replication. B0060 and B0078 originate from the same UAB study family (earlier and expanded analyses); do not count as two independent replications.

Original sources for this finding: Interactions between cannabidiol and commonly used antiepileptic drugs [CL21]

References and access status

[C_LABEL_D0043] ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE) TABLET [CAMBER PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: CAMBER PHARMACEUTICALS, INC.

Year: 2025

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL21] Interactions between cannabidiol and commonly used antiepileptic drugs

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Liu Y; Szaflarski JP; UAB CBD Program

Year: 2017

Source type: Open-label observational study

DOI: 10.1111/epi.13852

PMID: 28782097

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED31382177] Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Original source / bibliographic reference

Authors: Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP, UAB CBD Program.

Year: 2019

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.yebeh.2019.07.008

PMID: 31382177

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility